What Is a Micropeptide? Definition and What Research Reports

Definition

A micropeptide — used interchangeably in much of the literature with microprotein or smORF-encoded peptide (SEP) — is a very short protein, conventionally described as fewer than about 100 amino acids, that is translated from a small open reading frame (smORF) located in a transcript that genome annotation had previously classified as noncoding, such as a long noncoding RNA (lncRNA), a circular RNA, or the 5′ leader of an mRNA. The 2017 review Mining for Micropeptides described how ribosome profiling and mass spectrometry revealed that many transcripts labelled noncoding are in fact translated, and argued that these small translation products form an under-annotated layer of the proteome (PMID 28528987). In short: a micropeptide is defined by where its coding sequence hides and by how short it is, not by any pharmacological property.

What class of molecule is it, and where does it come from?

Micropeptides are ordinary polypeptides in chemical terms — chains of amino acids made by ribosomes from a messenger RNA — but they sit outside the historical protein catalogue because annotation pipelines routinely ignored open reading frames below a minimum length cut-off. Sources described in the literature include:

• lncRNA-derived smORFs, where a transcript classified as noncoding turns out to be translated; a 2015 Cell paper characterised a micropeptide encoded by a muscle-specific RNA that had been annotated as a lncRNA (PMID 25640239).
• Upstream and alternative reading frames within otherwise protein-coding mRNAs, discussed as a source of noncanonical translation products in a 2024 review of microprotein regulation of immunity (PMID 38734902).
• Alternative transcript isoforms: a 2025 Genome Biology study identified microprotein-coding intronic polyadenylation isoforms and examined their behaviour in the context of genotoxic anticancer drug response (PMID 41131620).

How the term is used in peptide research

"Micropeptide" belongs to molecular biology and cancer biology vocabulary. It describes an endogenous gene product discovered by sequencing and proteomics, and it is not a category of compound that is administered to people. That distinction matters because the word peptide is also used loosely for synthetic short-chain compounds studied in other settings; the papers below are about proteins a cell makes for itself, studied in cell lines, tissue samples and animal models. A 2024 review of multi-omic approaches summarised how transcriptomics, ribosome profiling and mass spectrometry are combined to nominate and validate cancer-related micropeptides, and noted that identification remains the field's central technical problem (PMID 39311199).

Researchers also use engineered micropeptides as laboratory tools rather than as subjects of study: a 2025 Nature report described a micropeptide "killswitch" used to probe the microenvironments of biomolecular condensates inside cells (PMID 40468084).

What the published literature reports

The evidence base is mechanistic and preclinical. Across the verified papers, individual micropeptides were reported to act on calcium handling, mitochondrial function, translation initiation and RNA binding rather than through a single shared mechanism.

Muscle

The 2015 Cell study reported that a micropeptide encoded by a putative long noncoding RNA regulated muscle performance, acting on the calcium-handling machinery of skeletal muscle in mice (PMID 25640239). It is frequently cited as the demonstration that a single very short translation product from a "noncoding" transcript can have a measurable physiological phenotype.

Cancer biology

Several groups reported micropeptides with roles in tumour models. A 2021 Molecular Cell paper described an "oncomicropeptide" named APPLE that promoted hematopoietic malignancy by enhancing translation initiation (PMID 34555354). A 2021 Journal of Clinical Investigation study reported that the micropeptide ASAP, encoded by LINC00467, promoted colorectal cancer progression by directly modulating ATP synthase activity (PMID 34591791). A 2025 Molecular Cell study reported that a hepatic micropeptide modulated mitochondrial RNA processing machinery in hepatocellular carcinoma models (PMID 40513568).

Immunity, kidney and nervous system

A 2024 review in Molecular Therapy summarised evidence that noncanonical microproteins participate in the regulation of immunity (PMID 38734902). A 2024 JCI study reported that the secreted micropeptide C4orf48 enhanced renal fibrosis through an RNA-binding mechanism (PMID 38625739). A 2023 Cell Death & Disease paper reported that a lncRNA-encoded mitochondrial micropeptide exacerbated microglia-mediated neuroinflammation in a retinal ischemia/reperfusion injury model (PMID 36792584), and a 2025 EMBO Reports piece described SERTM2 as a neuroactive entry in the growing micropeptide catalogue (PMID 40108405).

Examples described in the verified literature

Safety and Adverse Events: What Studies Report

The verified papers summarised here are discovery, mechanistic and preclinical studies in cells, tissue and animal models; none of them is a human clinical safety trial, and none reports human adverse-event rates, tolerability data or administered doses. Notably, the direction of effect reported in disease models is often harmful rather than beneficial — for example, researchers reported that a micropeptide enhanced renal fibrosis (PMID 38625739) and that another exacerbated neuroinflammation after retinal ischemia/reperfusion injury (PMID 36792584), which is why much of the cancer-focused work frames micropeptides as targets to inhibit rather than as agents to supply (PMID 34555354). This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision.

Limitations of the current literature

• Annotation uncertainty. Whether a given smORF produces a stable, functional protein remains contested, and the 2017 review framed micropeptide discovery as a mining problem requiring orthogonal evidence (PMID 28528987).
• Detection bias. Short, low-abundance products are hard to see by mass spectrometry, and the 2024 multi-omic review reported that combined approaches are generally needed to nominate credible candidates (PMID 39311199).
• Model dependence. Reported functions come from specific cell lines, tissues and injury or tumour models; the 2025 intronic polyadenylation study examined microprotein isoforms specifically in the context of genotoxic anticancer drug response (PMID 41131620).

References

• Mining for Micropeptides (Trends in Cell Biology, 2017)
• A micropeptide encoded by a putative long noncoding RNA regulates muscle performance (Cell, 2015)
• The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation (Molecular Cell, 2021)
• Micropeptide ASAP encoded by LINC00467 promotes colorectal cancer progression by directly modulating ATP synthase activity (Journal of Clinical Investigation, 2021)
• Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma (Molecular Cell, 2025)
• The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism (Journal of Clinical Investigation, 2024)
• A lncRNA-encoded mitochondrial micropeptide exacerbates microglia-mediated neuroinflammation in retinal ischemia/reperfusion injury (Cell Death & Disease, 2023)
• Noncanonical microprotein regulation of immunity (Molecular Therapy, 2024)
• Multi-Omic Approaches in Cancer-Related Micropeptide Identification (Proteomes, 2024)
• Probing condensate microenvironments with a micropeptide killswitch (Nature, 2025)
• SERTM2: a neuroactive player in the world of micropeptides (EMBO Reports, 2025)
• Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug response (Genome Biology, 2025)